

1. PRODUCT AND COMPANY IDENTIFICATION

1.1 Product identifiers

Product name : Acalabrutinib

Product Number : 10-4806

Brand : Focus Biomolecules

CAS-No. : 1420477-60-6

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : For Laboratory Research Use Only

1.3 Details of the supplier of the safety data sheet

Company : Focus Biomolecules

400 Davis Drive, Suite 600 Plymouth Meeting PA, 19462

Telephone : +1 855-362-8721

E-mail : support@focusbiomolecules.com

1.4 Emergency telephone number

Emergency Phone # : CHEMTREC 1-800-424-9300 (USA)

CHEMTREC 1-703-527-3887 (International)

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)

Health hazard, GHS08 STOT RE 1, H372

For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2 GHS Label elements, including precautionary statements

Pictogram

Signal word Hazard Danger

statement(s)

H301 Toxic if swallowed.

Precautionary statement(s)

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been

read and understood. Wash skin thoroughly after

P264 handling.

P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye

protection/ face protection.

P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON

CENTER/doctor. Rinse mouth.

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Acalabrutinib Page 1 of 7

2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Synonyms : 4-[8-Amino-3-[(2S)-1-but-2-ynoylpyrrolodon-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-

ylbenzamide

Hazardous components

Component	Classification	Concentration
Acalabrutinib		
	STOT RE 1, H372	95 - 100 %

For the full text of the H-Statements mentioned in this Section, see Section 16.

4. FIRST AID MEASURES

4.1 Description of first aid measures

General advice

Consult a physician. Show this safety data sheet to the doctor in attendance.

If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

In case of skin contact

Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.

In case of eye contact

Flush eyes with water as a precaution.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3 Indication of any immediate medical attention and special treatment needed

No data available

5. FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2 Special hazards arising from the substance or mixture

No data available

5.3 Advice for firefighters

Wear self-contained breathing apparatus for firefighting if necessary.

5.4 Further information

No data available

Acalabrutinib Page 2 of 7

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

For personal protection see section 8.

6.2 Environmental precautions

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up

Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

Reference to other sections

6.4 For disposal see section 13.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration before additional processing occurs.

Provide appropriate exhaust ventilation at places where dust is formed.

For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities Keep

container tightly closed in a dry and well-ventilated place.

Recommended storage temperature -20°C

Specific end use(s)

7.3 Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components with workplace control parameters

Contains no substances with occupational exposure limit values.

Hazardous components without workplace control parameters

8.2 Exposure controls

Appropriate engineering controls

Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.

Personal protective equipment

Eye/face protection

Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Body Protection

Complete suit protecting against chemicals, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Respiratory protection

Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Acalabrutinib Page 3 of 7

Control of environmental exposure

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties a)

Appearance Form: solid

b) Odor No data available No data available

c) Odor Threshold

d) pH No data availablee) Melting point/freezing No data available

point

f) Initial boiling point and No data available boiling range

g) Flash point No data available
h) Evaporation rate No data available

i) Flammability (solid, gas) No data availablej) Upper/lower No data available

flammability or explosive limits

Vapour pressure

explosive limits

l) Vapour density No data available m) Relative density No data available

n) Water solubility No data available

o) Partition coefficient: noctanol/water No data available

No data available

p) Auto-ignition temperature

No data available

q) Decomposition temperature

No data available

r) Viscosity No data available
 s) Explosive properties No data available
 t) Oxidizing properties No data available

9.2 Other safety information

No data available

10. STABILITY AND REACTIVITY

10.1 Reactivity

No data available

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

No data available

10.4 Conditions to avoid

No data available

10.5 Incompatible materials

Strong oxidizing agents, Acids and bases

10.6 Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx)

Acalabrutinib Page 4 of 7

the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity No data available

Inhalation: No data available Dermal: No data available

Skin corrosion/irritation

No data available

Serious eye damage/eye irritation No

data available

Respiratory or skin sensitisation No

data available

Germ cell mutagenicity

No data available

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable,

possible or confirmed human carcinogen by IARC.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known

or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of

regulated carcinogens.

Reproductive toxicity

No data available.

Specific target organ toxicity - single exposure

No data available

Specific target organ toxicity - repeated exposure

No data available

Aspiration hazard

No data available

Additional Information

Causes damage to the lymph nodes through prolonged or repeated exposure. Route of exposure: Oral

Acalabrutinib Page 5 of 7

RTECS: Not available

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

12. ECOLOGICAL

INFORMATION 12.1 Toxicity

No data available

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6 Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product

Offer surplus and non-recyclable solutions to a licensed disposal company.

Contaminated packaging

Dispose of as unused product.

14. TRANSPORT INFORMATION

DOT (US)

Not regulated

IMDG

Not regulated

IATA

Not regulated

15. REGULATORY INFORMATION

SARA 302 Components

This material does not contain any components with a section 302 EHS TPQ.

SARA 313 Components

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards

No SARA Hazards

Massachusetts Right To Know Components

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components

CAS-No. Revision Date

Acalabrutinib 1420477-60-6

California Prop. 65 Components

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

16. OTHER INFORMATION

Full text of H-Statements referred to under sections 2 and 3.

Acute Tox. Acute toxicity
H301 Toxic if swallowed.

H372 Causes damage to the lymph nodes through

prolonged or repeated oral exposure.

Further information

Copyright 2022 Focus Biomolecules. License granted to make unlimited paper copies for internal use only. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. Materials are intended for Laboratory Use only and must be used by qualified technicians. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Focus Biomolecules and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product.

Version: 1.0 Revision Date: 10/12/2022

Acalabrutinib Page 7 of 7